|
2023
|
Invention
|
Topical ruxolitinib for treating lichen planus.
The present disclosure relates to topical treatm... |
|
|
Invention
|
Ruxolitinib for the treatment of prurigo nodularis.
This disclosure relates to ruxolitinib, or a... |
|
|
Invention
|
Imidazopyridazine compounds and uses thereof.
Disclosed are compounds of Formula (I), methods of... |
|
|
Invention
|
Anti-pd-1/lag-3 bispecific antibodies and uses thereof. The present disclosure describes a bispec... |
|
|
Invention
|
Anti-pd-1/lag-3 bispecific antibodies and uses thereof.
The present disclosure describes a bispe... |
|
|
Invention
|
Process of preparing a pd-1/pd-l1 inhibitor.
The present invention relates to processes of prepa... |
|
|
Invention
|
Tricyclic triazolo compounds as dgk inhibitors.
The present application provides tricyclic triaz... |
|
|
Invention
|
Treatment of urticaria using jak inhibitors.
The present application provides methods of treatin... |
|
|
Invention
|
Treatment of urticaria using jak inhibitors. The present application provides methods of treating... |
|
|
Invention
|
Tetracyclic compounds as dgk inhibitors.
The present application provides tetracyclic compounds ... |
|
|
Invention
|
Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor.
Provided herein are compo... |
|
|
Invention
|
Fused tricyclic compounds as inhibitors of kras g12v mutants.
Disclosed are compounds of Formula... |
|
|
Invention
|
Fused tricyclic compounds as inhibitors of kras g12v mutants. Dislcosed are compounds of Formula ... |
|
|
Invention
|
Alk2 inhibitors for the treatment of anemia.
Provided herein are methods of treating anemia in a... |
|
|
Invention
|
Bicyclic amine cdk12 inhibitors. The present application provides bicyclic amines that are inhibi... |
|
|
Invention
|
Solid forms of a jak inhibitor and process of preparing the same. The present disclosure is relat... |
|
|
Invention
|
Solid forms of jak inhibitor and process of preparing the same.
The present disclosure is relate... |
|
|
Invention
|
Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of ... |
|
|
Invention
|
Tricyclic triazolo compounds as dgk inhibitors. The present application provides tricyclic triazo... |
|
|
Invention
|
Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active age... |
|
|
Invention
|
1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet pr... |
|
|
Invention
|
Treatment of b-cell malignancies by a combination jak and pi3k inhibitors.
This invention relate... |
|
|
Invention
|
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors.
This application relates to ... |
|
|
Invention
|
Tricyclic urea compounds as jak2 v617f inhibitors.
The present application provides tricyclic ur... |
|
|
Invention
|
Tricyclic urea compounds as jak2 v617f inhibitors. The present application provides tricyclic ure... |
|
|
Invention
|
Solid forms, salts, and processes of preparation of a cdk2 inhibitor. The present application pro... |
|
|
Invention
|
Methods of treating cancer with an fgfr inhibitor.
This application relates to methods of treati... |
|
|
Invention
|
Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof.
... |
|
|
Invention
|
Amorphous solid form of a bet protein inhibitor.
The present invention relates to an amorphous s... |
|
|
Invention
|
Bicyclic heterocycles as fgfr inhibitors.
The present invention relates to bicyclic heterocycles... |
|
|
Invention
|
Pyrrolotriazine compounds as tam inhibitors.
This application relates to compounds of Formula I:... |
|
|
Invention
|
Pd-l1/sting conjugates and methods of use.
The present application relates to conjugates of STIN... |
|
2022
|
Invention
|
Topical formulation for a jak inhibitor.
This invention relates to pharmaceutical formulations f... |
|
|
Invention
|
Biomarkers for vitiligo.
Biomarkers are provided that are associated with or predictive of a sub... |
|
|
Invention
|
Treatment paradigm for an anti-cd19 antibody therapy.
The present disclosure provides anti-CD19 ... |
|
|
Invention
|
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof. RSHbaa]pyrazin-7-o... |
|
|
Invention
|
Bicyclic amines as cdk2 inhibitors.
The present application provides bicyclic amines of Formula ... |
|
|
Invention
|
Topical treatment of vitiligo by a jak inhibitor.
The present disclosure relates to topical trea... |
|
|
Invention
|
Anti-mutant calreticulin (calr) antibodies and uses thereof.
Anti-mutant calreticulin (mutCALR) ... |
|
|
Invention
|
Bicyclic amine cdk12 inhibitors.
The present application provides bicyclic amines that are inhib... |
|
|
Invention
|
Combination therapy comprising an fgfr inhibitor and a kras inhibitor.
The present disclosure re... |
|
|
Invention
|
Ruxolitinib formulation for reduction of itch in atopic dermatitis.
This disclosure relates to m... |
|
|
Invention
|
Heterocyclic compounds as immunomodulators.
Disclosed are compounds of Formula (I′), methods of ... |
|
2021
|
Invention
|
Topical treatment of vitiligo.
The present disclosure relates to topical treatment of vitiligo u... |
|
2010
|
G/S
|
Pharmaceutical preparations for use in the treatment of oncological, hematological and inflammato... |
